{"disease":{"id":"oesophago-gastric-carcinoma","name":"oesophago gastric carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07260734","title":"AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT03006432","title":"PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":507,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT06669663","title":"Hypoxia Driven Metabolic Response in Oesophagogastric Adenocarcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Imperial College London","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}